Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe

2017 ◽  
Vol 55 (6) ◽  
pp. 819-827 ◽  
Author(s):  
Marion Ingeborg Boldingh ◽  
Angelina Maniaol ◽  
Cathrine Brunborg ◽  
Luuk Dekker ◽  
Alexander Lipka ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Northern Europe ◽  
Clinical Aspects

Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis

1988 ◽  
Vol 9 (2) ◽  
pp. 141-145 ◽  
Author(s):  
R. Mantegazza ◽  
D. Pareyson ◽  
F. Baggi ◽  
P. Romagnoli ◽  
D. Peluchetti ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Aspects ◽  
Achr Antibody

scholarly journals Geographical Distribution of Myasthenia Gravis in Northern Europe - Results from a Population-Based Study from Two Countries

2015 ◽  
Vol 44 (4) ◽  
pp. 221-231 ◽  
Author(s):  
Marion I. Boldingh ◽  
Angelina H. Maniaol ◽  
Cathrine Brunborg ◽  
Luuk Dekker ◽  
Anne T. Heldal ◽  
...  
Keyword(s):  
The Netherlands ◽  
Myasthenia Gravis ◽  
Antibody Test ◽  
Population Based ◽  
Cross Sectional Study ◽  
Northern Europe ◽  
Cross Sectional ◽  
Immunological Markers ◽  
Environmental Interactions ◽  
Positive Antibody

Objectives: To compare the prevalence of myasthenia gravis (MG) subgroups based on immunological markers and clinical presentation in two geographically complete MG populations in northern Europe. Methods: This cross-sectional study included all living MG patients in Norway and a regional cohort from the Netherlands. Patients were identified using their hospital registration codes. Medical charts of subjects >16 years were reviewed. Inclusion criteria were clinical MG, a positive antibody test for acetylcholine receptor (AChR MG) or muscle-specific kinase (MuSK MG), or if seronegative MG, confirmed by an electrophysiological test. Results: 1,205 MG patients (534 Norwegians and 671 Dutch) fulfilled the criteria, giving a higher point prevalence in the Netherlands (167/million, 95% CI 155-180) than in Norway (138/million, 95% CI 126-150). In particular, rates of AChR MG (143 vs. 111/million), MuSK MG (6.5 vs. 0.5/million), and ocular phenotype (62 vs. 24/million) were higher in the Netherlands. Conclusion: Novel findings are an AChR MG geographical north-south gradient and a 2.6-fold more ocular MG patients in the Netherlands than in Norway. The MuSK MG latitudinal gradient supports the notion of a north-south gradient in Europe, with a higher prevalence in the south. The variation is probably explained by genetic differences between the populations, in addition to environmental interactions.

scholarly journals Epidemiological profile of myasthenia gravis patients at the Neuromuscular Diseases Service of the Hospital de Clínicas of the Federal University of Paraná

2021 ◽  
Author(s):  
Isabelle Caroline Fasolo Normandia Moreira ◽  
Rie Tiba Maglioni ◽  
Renata Dal- Prá Ducci ◽  
Cláudia Suemi Kamoi Kay ◽  
Otto Jesus Hernandez Fustes ◽  
...  
Keyword(s):  
Mental Health ◽  
Myasthenia Gravis ◽  
Mental Health Disorders ◽  
Pathological Diagnosis ◽  
Clinical Aspects ◽  
Repetitive Nerve Stimulation ◽  
Cross Sectional ◽  
Patient Profile ◽  
Health Disorders ◽  
Epidemiological Profile

Background: Myasthenia Gravis (MG) is an autoimmune disease of the neuromuscular junction. In Brazil, epidemiological data regarding MG and its clinical aspects are limited. Objectives: The aim of this study was to describe the clinical and epidemiological profile of patients with MG at a referral center. Design and setting: Cross-sectional observational study performed on patients with Myasthenia Gravis age 18 years and older at Federal University of Paraná. Methods: Data were obtained through clinical evaluation and medical records. Results: The sample comprised 100 patients (67 females and 33 males). The median age at last appointment was 49.5 years (IQR 37-61). AntiAchR antibody was positive in 79 patients. Anti-MuSK antibody was positive in 6 positive patients. The Repetitive Nerve Stimulation (RNS) test presented abnormal result in 89 individuals. The main comorbidities reported were systemic arterial hypertension (SAH) (35%), mental health disorders (23%), diabetes mellitus (DM) (21%), dyslipidemia (18%), and hypothyroidism (13%). During the study period, the patients were on the following medications: pyridostigmine (88%), prednisone (42%), azathioprine (45%), cyclosporine (13%), and mycophenolate (6%). Thymectomy was performed in 30 patients, of whom 6 had a pathological diagnosis of thymoma, and five a pathological diagnosis of thymic hyperplasia. Conclusion: The patient profile as well as the prevalence of comorbidities in our MG sample were similar to previous studies. We also found that our sample presented a higher incidence of SAH, DM, mental health disorders and hypothyroidism compared with the general population.

Immunological and Clinical Aspects of Neonatal Myasthenia Gravis

1987 ◽  
Vol 505 (1 Myasthenia Gr) ◽  
pp. 879-880 ◽  
Author(s):  
EVELYNE MOREL ◽  
BRUNO EYMARD
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Aspects

scholarly journals Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture

Cells ◽  
2019 ◽  
Vol 8 (7) ◽  
pp. 671 ◽  
Author(s):  
Inga Koneczny ◽  
Ruth Herbst
Keyword(s):  
Myasthenia Gravis ◽  
Low Density Lipoprotein ◽  
Treatment Strategies ◽  
Density Lipoprotein ◽  
Clinical Aspects ◽  
Pathogenic Mechanisms ◽  
Skeletal Muscle Weakness ◽  
Density Lipoprotein Receptor ◽  
Muscle Specific Kinase ◽  
And Function

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ). Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein receptor-related protein 4 (Lrp4), that lead by a range of different pathogenic mechanisms to altered tissue architecture and reduced densities or functionality of AChRs, reduced neuromuscular transmission, and therefore a severe fatigable skeletal muscle weakness. In this review, we give an overview of the history and clinical aspects of MG, with a focus on the structure and function of myasthenic autoantigens at the NMJ and how they are affected by the autoantibodies’ pathogenic mechanisms. Furthermore, we give a short overview of the cells that are implicated in the production of the autoantibodies and briefly discuss diagnostic challenges and treatment strategies.

Thymoma and myasthenia gravis: clinical aspects and prognosis

2012 ◽  
Vol 20 (1) ◽  
pp. 48-52 ◽  
Author(s):  
Konstantinos Vachlas ◽  
Charalambos Zisis ◽  
Dimitra Rontogianni ◽  
Antonios Tavernarakis ◽  
Argini Psevdi ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Aspects

scholarly journals Burden of disease in myasthenia gravis: taking the patient’s perspective

2021 ◽  
Author(s):  
Sophie Lehnerer ◽  
Jonas Jacobi ◽  
Ralph Schilling ◽  
Ulrike Grittner ◽  
Derin Marbin ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Low Income ◽  
Burden Of Disease ◽  
Short Form ◽  
Female Gender ◽  
Well Being ◽  
Clinical Aspects ◽  
Control Group ◽  
Sf 36 ◽  
Lower Hrqol

Abstract Background Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but also psychological and social well-being are limited. We aim to describe the burden of disease in MG including sociodemographic, economical, psychosocial as well as clinical aspects, to compare health-related quality of life (HRQoL) of patients with MG to the general population (genP) and to explore risk factors for a lower HRQoL. Methods This case–control study was conducted with MG patients of the German Myasthenia Association. A questionnaire-based survey included sociodemographic and clinical data as well as standardized questionnaires, e.g. the Short Form Health (SF-36). HRQoL was compared to genP in a matched-pairs analysis. Participants of the German Health Interview and Examination Survey for Adults (DEGS1) served as control group. Results In our study, 1660 MG patients participated and were compared to 2556 controls from the genP. Patients with MG showed lower levels of physical functioning (SF-36 mean 56.0, SD 30.3) compared to the genP (mean 81.8, SD 22.1, adjusted difference: 25, 95% CI 22–29) and lower mental health sub-score (SF-36 mean 67.3, SD 19.8, vs. 74.1, SD 16.7, adjusted difference: 5, 95% CI 2–8). Female gender, higher age, low income, partnership status, lower activities of daily life, symptoms of depression, anxiety and fatigue and self-perceived low social support were associated with a lower HRQoL in MG patients. Discussion HRQoL is lower in patients with MG compared to genP. The burden of MG on patients includes economic and social aspects as well as their emotional well-being. New therapies must achieve improvements for patients in these areas. Trial registration information Clinicaltrials.gov, NCT03979521, submitted: June 7, 2019, first patient enrolled: May 1, 2019, https://clinicaltrials.gov/ct2/show/NCT03979521

Preclinical operative dentistry courses in northern Europe and Scandinavia

1993 ◽  
Vol 57 (4) ◽  
pp. 312-317
Author(s):  
NH Wilson ◽  
A Richards ◽  
J Laverock ◽  
MS Purkiss
Keyword(s):  
Northern Europe ◽  
Operative Dentistry
Sign in / Sign up

Export Citation Format

Share Document